BACKGROUND: To identify distinct depressive symptom trajectories in the TORDIA study and determine their correlates. METHODS:Latent Class Growth Analysis (LCGA) using the Children's Depression Rating Scale-Revised (CDRS-R) through 72 weeks from intake. RESULTS: 3 classes were identified: (1) little change in symptomatic status ("NO"), comprising 24.9% of participants, with a 72-week remission rate of 25.3%; (2) slow, steady improvement ("SLOW"), comprising 47.9% of participants, with a remission rate of 60.0%, and (3) rapid symptom response ("GO"), comprising 27.2% of participants, with a remission rate of 85.7%. Higher baseline CDRS-R (p<0.001) and poorer functioning (p=0.03) were the strongest discriminators between NO and GO. Higher baseline CDRS (p<0.001) and scores on the Mania Rating Scale (MRS) (p=0.01) were the strongest discriminators between SLOW and GO. Other variables differentiating GO from both NO and from SLOW, were better baseline functioning, lower hopelessness, and lower family conflict. Both NO and SLOW showed increases on the MRS over time compared to GO (ps ≤ 0.04), and increasing MRS was strongly associated with lack of remission by 72 weeks (p=0.02). LIMITATIONS: High rate of open treatment by the end of the follow-up period creates difficulty in drawing clear inferences about the long-term impact of initial randomization. CONCLUSION: Along with depressive severity, sub-syndromal manic symptoms, at baseline, and over time emerged as important predictors and correlates of poor outcome in this sample. Further research is needed on the treatment of severe depression, and on the assessment and management of sub-syndromal manic symptoms in treatment resistant depression. Copyright Â
RCT Entities:
BACKGROUND: To identify distinct depressive symptom trajectories in the TORDIA study and determine their correlates. METHODS: Latent Class Growth Analysis (LCGA) using the Children's Depression Rating Scale-Revised (CDRS-R) through 72 weeks from intake. RESULTS: 3 classes were identified: (1) little change in symptomatic status ("NO"), comprising 24.9% of participants, with a 72-week remission rate of 25.3%; (2) slow, steady improvement ("SLOW"), comprising 47.9% of participants, with a remission rate of 60.0%, and (3) rapid symptom response ("GO"), comprising 27.2% of participants, with a remission rate of 85.7%. Higher baseline CDRS-R (p<0.001) and poorer functioning (p=0.03) were the strongest discriminators between NO and GO. Higher baseline CDRS (p<0.001) and scores on the Mania Rating Scale (MRS) (p=0.01) were the strongest discriminators between SLOW and GO. Other variables differentiating GO from both NO and from SLOW, were better baseline functioning, lower hopelessness, and lower family conflict. Both NO and SLOW showed increases on the MRS over time compared to GO (ps ≤ 0.04), and increasing MRS was strongly associated with lack of remission by 72 weeks (p=0.02). LIMITATIONS: High rate of open treatment by the end of the follow-up period creates difficulty in drawing clear inferences about the long-term impact of initial randomization. CONCLUSION: Along with depressive severity, sub-syndromal manic symptoms, at baseline, and over time emerged as important predictors and correlates of poor outcome in this sample. Further research is needed on the treatment of severe depression, and on the assessment and management of sub-syndromal manic symptoms in treatment resistant depression. Copyright Â
Authors: Fadi T Maalouf; David Brent; Luke Clark; Lucy Tavitian; Rebecca Munnell McHugh; Barbara J Sahakian; Mary L Phillips Journal: J Affect Disord Date: 2011-05-26 Impact factor: 4.839
Authors: J J Dunkin; A F Leuchter; I A Cook; J E Kasl-Godley; M Abrams; S Rosenberg-Thompson Journal: J Affect Disord Date: 2000-10 Impact factor: 4.839
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: Rasim Somer Diler; Tina R Goldstein; Danella Hafeman; Brian Thomas Rooks; Dara Sakolsky; Benjamin I Goldstein; Kelly Monk; Mary Beth Hickey; David Axelson; Satish Iyengar; Boris Birmaher Journal: Bipolar Disord Date: 2017-06-14 Impact factor: 6.744
Authors: Jennifer B Dwyer; Argyris Stringaris; David A Brent; Michael H Bloch Journal: J Child Psychol Psychiatry Date: 2020-02-04 Impact factor: 8.982
Authors: Marissa J Luft; Martine Lamy; Melissa P DelBello; Robert K McNamara; Jeffrey R Strawn Journal: Curr Probl Pediatr Adolesc Health Care Date: 2018-01-19
Authors: Zuzanna K Wojcieszak; Rebekah J Mennies; Daniel N Klein; John R Seeley; Thomas M Olino Journal: Res Child Adolesc Psychopathol Date: 2021-02-20
Authors: Rasim Somer Diler; Tina R Goldstein; Danella Hafeman; John Merranko; Fangzi Liao; Benjamin I Goldstein; Heather Hower; Mary Kay Gill; Jeffrey Hunt; Shirley Yen; Martin B Keller; David Axelson; Michael Strober; Satish Iyengar; Neal D Ryan; Boris Birmaher Journal: J Child Adolesc Psychopharmacol Date: 2017-02-28 Impact factor: 2.576
Authors: Manivel Rengasamy; Brandon M Mansoor; Robert Hilton; Giovanna Porta; Jiayan He; Graham J Emslie; Taryn Mayes; Gregory N Clarke; Karen Dineen Wagner; Martin B Keller; Neal D Ryan; Boris Birmaher; Wael Shamseddeen; Joan Rosenbaum Asarnow; David A Brent Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-04 Impact factor: 8.829
Authors: Danella Hafeman; David Axelson; Christine Demeter; Robert L Findling; Mary A Fristad; Robert A Kowatch; Eric A Youngstrom; Sarah McCue Horwitz; L Eugene Arnold; Thomas W Frazier; Neal Ryan; Mary Kay Gill; Jessica C Hauser-Harrington; Judith Depew; Brieana M Rowles; Boris Birmaher Journal: Bipolar Disord Date: 2013-03-25 Impact factor: 6.744
Authors: Sara J Becker; Anthony Spirito; Lynn Hernandez; Nancy P Barnett; Cheryl A Eaton; William Lewander; Damaris J Rohsenow; Peter M Monti Journal: Drug Alcohol Depend Date: 2012-05-04 Impact factor: 4.492